Pre-made Tocilizumab benchmark antibody ( Whole mAb, anti-IL6R therapeutic antibody, Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-584

Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-584-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody
INN Name Tocilizumab
TargetIL6R
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2004
Year Recommended2004
CompaniesAssistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh
Conditions ApprovedDrug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis
Conditions ActiveAdult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer
Conditions DiscontinuedChronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus
Development Techna